Swiss Cancer Institute
Clinical trials sponsored by Swiss Cancer Institute, explained in plain language.
-
New hope for lung cancer patients when immunotherapy fails
Disease control Not yet recruitingThis study tests a new combination of two drugs—gemcitabine (a chemotherapy) and ivonescimab (a targeted therapy)—in 47 people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if the combo can shrink tumors and offe…
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 17, 2026 06:31 UTC
-
Magnesium may strengthen immune therapy for advanced lung cancer
Disease control Not yet recruitingThis study tests whether adding magnesium to standard chemo-immunotherapy helps people with advanced non-small cell lung cancer (stage III or IV). About 230 participants will receive either magnesium or a placebo, without knowing which. The goal is to see if magnesium improves su…
Phase: PHASE2, PHASE3 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 17, 2026 06:19 UTC
-
Timing is everything: morning infusions may boost melanoma treatment
Disease control Not yet recruitingThis study looks at whether giving immunotherapy earlier in the day can help people with advanced melanoma live longer without their cancer growing. Researchers will compare morning versus later-day infusions in 108 adults. The goal is to see if matching treatment timing with the…
Phase: PHASE4 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 13, 2026 16:02 UTC